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Abstract A stereoselective synthesis of (1RS,2SR,6SR)-7-benzyl-6-cyclobutyl-2-
methoxymethyl-4,7-diaza-9-oxobicyclo[4.3.0]nonan-8-one, representative of 
a novel series of selective muscarinic (M1) receptor agonists, is described. 
Key words piperidines, oxazolidinones, hydroboration, muscarinic receptors, 
trifluoroacetimidates . 
 
Agonists of muscarinic M1 receptors have been identified as 
potential chemotherapeutic agents for the treatment of 
Alzheimer’s disease.1 In particular, they could provide 
alternatives to cholinesterase inhibitors that tend to lose 
efficacy over time. Indeed several M1 receptor agonists have 
been found to alieviate the symptoms of Alzheimer’s disease.2 It 
is, however, crucial to find compounds selective for M1 
receptors  to avoid side- effects arising from stimulation of other 
muscarinic receptor subtypes.  Early modelling studies using the 
bovine rhodopsin as a substitute for the M1 receptor, led to the 
identification of the oxazolidinonylpiperidines 1 and 2 as 
possibly selective M1 agonists, see Figure 1.3 We now describe a 
stereoselective synthesis of the first representative of these 
novel compounds.   
 
Figure 1 Oxazolidinonylpiperidines of interest as M1 receptor 
agonists 
 
The first member of the series selected for synthesis was the 7-
benzyl-6-cyclobutyl-2-methoxymethyl analogue 3. The 
oxazolidinone 4 was identified as a likely precursor of the 
piperidine 3 and the alkenyloxazolidinone 5, possibly accessible 
from the aldehyde 6, was considered a plausible intermediate 
for the synthesis of the oxazolidinone 4. The aldehyde 6 is the 
equivalent of an alkylated, reduced serine derivative but the 
presence of the cyclobutyl group limited the options available 
for its synthesis. In the end, it was decided to study a 
preparation of the aldehyde 6 from the ketone 7 that in turn 
would be prepared from the commercially available cyclobutane 
carboxylic acid 8, see Figure 2. Although not unreasonable, it 
was recognised that the stereoselectivities of several of the 
steps in this proposed synthesis were difficult to predict.   
 
Figure 2 Proposed synthesis of the oxazolidinonylpiperidine 3 
A synthesis of the racemic modification of the aldehyde 6 is 
outlined in Scheme 1. The tert-butyldimethylsilyloxymethyl 
ketone 7 was prepared in four steps from cyclobutanecarboxylic 
acid by conversion into the methyl ketone 9, bromination of the 
ketone and hydrolysis of the known4 bromide 10 to give the 
corresponding alcohol that was protected as its silyl ether 7. A 
Wadsworth-Emmons-Horner reaction of the protected 
hydroxyketone 7 followed by reduction of the resulting -
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unsaturated esters gave a 75 : 25 mixture of the geometrical 
isomers of the alcohols 11, the major alcohol being identified as 
the (Z)-isomer on the basis of a significant nOe between 2-H and 
3-CH. This mixture of alcohols was converted into the 
corresponding trifluoroacetimidates 12 by reaction with 
trifluoroacetonitrile, and heating the trifluoroacetimidates 
initiated a [3,3]-sigmatropic rearrangement to give the racemic 
tertiary trifluoroacetamide 13.5 Cleavage of the 
trifluoroacetamide was carried out under mild conditions using 
sodium borohydride in ethanol and the resulting amine 14 was 
converted into its Cbz-derivative 15 that was ozonolysed to give 
the required aldehyde (±)-6, see Scheme 1.     
Scheme 1 Synthesis of the aldehyde (±)-6 Reagents and 
conditions (i) MeLi, Et2O, 0 oC to rt, 3 h (90%); (ii) Br2, MeOH, 0 
oC to 15 oC, 1.5 h (80%); (iii) (a) KOCHO, MeOH, heat under 
reflux, 12 h (71%) (b) TBSCl, imid., DMAP (cat.), TBAI (cat.), 
DCM, rt, 1 h (62%); (iv) (a) (EtO)2P(O)CH2CO2Et, NaH, THF, rt, 
45 min, add 7, rt, 2.5 h (b) DIBAL-H, hexanes, THF, 78 oC, 3h, rt, 
30 min [89% from 7, (Z) : (E) = 75 : 25]; (v) NaH, THF, rt, 1 h, 
add to CF3CN, THF, 115 oC to 78 oC, 1 h (88%); (vi) xylene, 
heat under reflux 18 h (91%); (vii) NaBH4, EtOH, 0 oC to rt, 18 h 
(80%); (viii) CBzCl, Et3N, DCM, rt, 18 h (83%); (ix) O3, DCM, 78 
oC, then Ph3P, rt (84%).  
The next step was the conversion of the aldehyde 6 into the 
oxazolidinone 5. This was achieved in one pot using an excess of 
isopropenylmagnesium bromide with a prolonged reaction time 
to facilitate cyclisation.6 This reaction was highly stereoselective 
and gave the cyclised product 5 exclusively. The formation of 
this oxazolidinone is consistent with addition of the Grignard 
reagent onto the less hindered face of the chelated, 
deprotonated aldehyde 16 to give the adduct 17. This cyclised 
in situ, possibly via the isocyanate 18 formed by loss of lithium 
benzyloxide, to give the oxazolidinone after work-up, see 
Scheme 2. The structure asigned to the oxazolidinone 5 was 
confirmed by X-ray difraction,7 see Figure 3.  
To convert the oxazolidinone 5 into the cyclisation precursor 4 
it was necessary to oxidise the methyl group, benzylate the 
oxazolidinone and hydrate the alkene stereoselectively. These 
conversions are outlined in Scheme 3. Epoxidation of the alkene 
5 gave a mixture of the epoxides 19 and 20, ratio 77 : 23, that 
were reacted as a mixture with lithium 2,2,6,6-
tetramethylpiperidide8 to give the allylic alcohol 21.   
 
Scheme 2 Preparation of the oxazolidinone 5 Reagents and 
conditions (i) CH3C(MgBr)=CH2, THF, tol., 78 oC, 2h then rt, 48 h 
(66%).  
 
Figure 3 The structure of the oxazolidinone 5 as established by 
X-ray diffraction.  
Alkylation using sodium hydride-benzyl bromide gave the N-
benzyloxazolidinone 23 as the major product with the bis-
benzylated material 22 as only a minor side-product. 
Methylation of the alcohol 23 led to the methyl ether 24 and 
hydroboration-oxidation of this alkene using borane in THF at 0 
oC gave a mixture of the epimeric alcohols 4 and 25, ratio 4 : 25 
= 85 : 15,9 see Scheme 3.  
Scheme 3 Synthesis of the (±)-oxazolidinone 4 Reagents and 
conditions (i) (i) mCPBA, DCM, rt, 18 h (75%); (ii) 2,2,6,6-
tetramethylpiperidine, THF, nBuLi, 0 oC to rt, 1 h, added to 19 
and 20, THF, 0 oC to rt, 3 h (67%); (iii) NaH, BnBr, THF, heat 
under reflux, 6 h (23, 79%; 22, 6%); (iv) NaH, THF, MeI, rt, 18 h 
(90%); (v) BH3, THF, 0 oC, 18 h, then EtOH, NaOAc, 30% aq. 
H2O2, heat under reflux 1 h (95%, 4 : 25 = 85 : 15). 
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The mixture of hydroboration products was not separated and 
the structure 4 of the major product, which turned out to be the 
required epimer, was only confirmed later in the synthesis. The 
stereoselectivity can be explained by participation of transition 
structure 26 in the hydroboration step, see Figure 4, but 
molecular modelling studies of the hydroboration were not 
carried out.   
 
Figure 4 Facial selectivity of the hydroboration of alkene 24 
The completion of the synthesis of the oxazolidinonylpiperidine 
3 is outlined in Scheme 4. Desilylation of the mixture of the 
hydroboration products 4 and 25 gave a mixture of the diols 27 
and 28 that was converted into the N-benzylpiperidines 30 and 
31, ratio ca. 85 : 15, by reaction of the mesylates 29 with an 
excess of benzylamine.10 Following separation of the major N-
benzylpiperidine 30 by chromatography, a selective transfer 
hydrogenolysis of the piperidine N-benzyl group gave the 
required oxazolidinonylpiperidine 3.11       
 
Scheme 4 Completion of a synthesis of the (±)-
oxazolidinonylpiperidine 3 Reagents and conditions (i) TBAF, 
THF, 0 oC to rt, 30 min (67%, 27 : 28 = 85 : 15); (ii) MsCl, Et3N, 
DCM, 0 oC to rt, 1 h; (iii) BnNH2, 80 oC, 18 h (30, 36%; mixture of 
30 and 31, 26%, 30 : 31 = 55 : 45); (iv) 10% Pd/C, HCO2H, 
MeOH, rt, 20 min (71%); (v) BBr3, DCM, THF, 0 oC, 4 h (61%). 
 
The structures of the products shown in Scheme 4 were 
consistent with their spectroscopic data, although the 
configurations of the oxazolidinonylpiperidines at C2 were 
difficult to assign from their 1H NMR spectra. The structures of 
these products were eventually confirmed by selective 
demethylation of the major N-benzylpiperidine 30 to give the 
alcohol 32 that was crystalline and whose structure was 
confirmed by X-ray diffraction,7 see Figure 5.  The vicinal 
coupling constant J1,2 of the oxazolidinonylpiperidines was 
found to be diagnostic of their relative configuration at C2, being 
less than 5 Hz for the major products 3, 30 and 32, and greater 
than 8 Hz for the minor product 31.    
 
Figure 5 The structure of the (±)-oxazolidinonylpiperidine 32 
as established by X-ray data.  
This work has resulted in the synthesis of the first member of a 
novel series of compounds, oxazolidinonylpiperidines, of 
interest as potentially selective ligands for muscarinic receptors. 
Indeed the methyl ether 3 was found to be a 50% partial agonist 
of muscarinic M1 receptors with micromolar potency, as 
measured by the relaxation responses of rat duodenum 
compared with the full agonist McN-A-343. Of interest in the 
synthetic work was the stereoselectivities of the Grignard 
addition and hydroboration steps and the overall strategy. This 
chemistry has been applied to the synthesis of 
oxazolidinonylpiperidines with both alkoxymethyl and hetaryl 
sybstituents at C2. This work will be decribed in full elsewhere.  
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63.4, 71.4, 73.6, 127.8, 127.8, 128.7, 138.1 and 158.7; m/z (CI+) 
331 (M+ + 1, 60%) and 91 (100). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
